BioSpace News Archive

Medtech leader Medcura Inc. has added two new leadership team members with extensive experience in science, product development and compliance.

Mati Therapeutics Inc. announced that it has completed and now occupies a facility dedicated to manufacturing all products formulated in Mati’s proprietary Evolute® sustained ocular drug delivery platform.

Milestone Scientific Inc., a leading developer of computerized drug delivery instruments that provide painless and precise injections, announced the appointment of Dr. Didier Demesmin, MD, MBA, to the Board of Directors.

GENinCode Plc (AIM - GENI), the polygenics company focused on the prevention of cardiovascular disease, announced the presentation by Kaiser Permanente on the ‘Utility of the CARDIO inCode-Score CHD polygenic risk score for incident coronary heart disease interplay with lifestyle in a multi-ethnic cohort of more than 60,000 individuals.’

Moonshot is excited to announce that its incubator client, Axolotl Biologix, based in its NACET Flagstaff, Arizona campus, has finalized a merger with Carmell Therapeutics.

The newly renamed Montefiore Einstein Comprehensive Cancer Center has been awarded comprehensive designation by the National Cancer Institute of the National Institutes of Health, the ultimate standard achieved by only 55 other NCI cancer centers in the U.S. Through NCI’s peer-review process, MECCC was nationally recognized for its paradigm-shifting, practice-changing, policy-impacting cancer-focused science.

Novadiscovery, a life sciences company leading AI-driven in silico clinical trial simulation with its jinkō platform to inform and optimize the next-generation trial design, today announced the accurate, prospective prediction of results from AstraZeneca phase III FLAURA2 trial.

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced its decision to discontinue the Phase 3 LIMT-2 study of peginterferon lambda in patients with chronic hepatitis delta (CHD).

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the speakers for its upcoming Investor & Analyst Event on Tuesday, September 19 from 9:00 a.m. to 1:00 p.m. Eastern Time in New York.

Dyadic International, Inc. today announced that Joseph Hazelton, Chief Business Officer of Dyadic will be presenting at BioProcess International.